Kuano.ai, a London, UK-based provider of a software platform for quantum modelling of enzymes, raised £1m in seed funding.
Backers included ACF Investors, o2h Ventures and a syndicate of Cambridge-based angel investors.
The company intends to use the funds to expand the technology team and further develop its platform and asset development, including its own range of novel therapeutics and creating a data bank for use in its work with academic and commercial partners.
Led by Dr. Vid Stojevic, Co-Founder CEO, Kuano combines quantum physics, artificial intelligence (AI) and medicinal chemistry to discover therapeutics focused on enzyme inhibition. The company is using its platform to advance its own pipeline of novel therapeutics targeting unmet medical needs, as well as in collaborative programs with leading academic and commercial partners. This includes a recent research collaboration with Alzheimer’s Research UK University College London Drug Discovery Institute to identify inhibitors for treating degenerative neurological disorders.
FinSMEs
12/07/2021
